ChiCTR1900022391
尚未开始
/
/
/
2019-04-09
/
/
不育症
A pragmatic, multi-centre, three-arm randomised controlled trial to assess the clinical effectiveness and safety of time lapse imaging in in-vitro fertilisation treatment
A pragmatic, multi-centre, three-arm randomised controlled trial to assess the clinical effectiveness and safety of time lapse imaging in in-vitro fertilisation treatment.
Primary objectives: The primary objective of the trial is to determine if the use of TLI or undisturbed culture in IVF/ICSI treatment results in a higher live birth rate when compared to current standard methods of embryo incubation and assessment. Secondary objectives: The trial aims to answer the following questions and the secondary objectives of the trial are: 1. To obtain measures of clinical effectiveness of TLI/undisturbed culture: (1) Are clinical pregnancy rates and implantation rates increased with the use of TLI/undisturbed culture in IVF/ICSI treatment? Does the use of TLI/undisturbed culture increase the number of women having an elective single embryo transfer? 2. To obtain measures of clinical safety of TLI/undisturbed culture: (1) Does the use of TLI/undisturbed culture decrease the incidence of multiple births following IVF/ICSI treatment? (2) Does the use of TLI/undisturbed culture decrease the incidence of miscarriages following IVF/ICSI treatment? (3) Are stillbirths and major congenital abnormalities at birth decreased with the use of TLI/undisturbed culture in IVF/ICSI treatment?
随机平行对照
探索性研究/预试验
Randomisation will be performed on the day of fertilisation check. Participants satisfying all the eligibility criteria for the trial will be randomised into one of the three treatment arms in a 1:1:1 ratio. 1) time-lapse imaging 2) undisturbed culture 3) standard treatment Randomisation will be done by a trained
It will not be possible to blind embryologists to the intervention. All other local and central trial staff, including clinicians performing the embryo transfer and data analysts, will be blinded. Participants will be blinded to the allocated intervention until the end of their participation in the trial. This will either be a negative pregnancy test which is approximately 2 weeks after embryo transfer or the end of their pregnancy.
香港中文大學婦產科學系
/
525
/
2018-02-01
2021-07-31
/
The inclusion criteria are broad in keeping with the latest NICE guidelines (2013) for NHS funded IVF/ICSI treatment. Participants undergoing IVF/ICSI treatment and 1) the woman is between 18 and 42 years of age at the time of consent; 2) the male partner is at least 18 years of age at the time of consent; 3) receiving the first, second or third IVF/ICSI treatment cycle; 4) both partners give written informed consent; 5) those having at least 3 2PN embryos (showing 2 pro-nucleii which is a sign of normal fertilisation) on day of fertilization check.；
登录查看1) Participants who have been randomised previously to this trial; 2) Participants concomitantly participating in other trials; 3) IVF/ICSI treatment using donor gametes; 4) Planned pre-implantation genetic diagnostics or screening (PGS/PGD).；
登录查看香港中文大學婦產科學系
/
药渡2025-01-19
亚泰制药2025-01-19
亚泰制药2025-01-19
约印创投2025-01-16
求实药社2025-01-16
Genhouse2025-01-16
IPHASE2025-01-16
动脉网2025-01-16
动脉网-最新2025-01-16
药明康德2025-01-16
浙公网安备33011002015279
本网站未发布麻醉药品、精神药品、医疗用毒性药品、放射性药品、戒毒药品和医疗机构制剂的产品信息
友情链接: 摩熵医药 摩熵医药企业版 摩熵化学MolAid 晓材Matmole 摩熵医学MedXYZ 载体质粒 觅健肿瘤互助 动脉网 药物百科
